Fri, Sep 19, 2014, 1:02 PM EDT - U.S. Markets close in 2 hrs 58 mins

Recent

% | $
Quotes you view appear here for quick access.

Roche Holding AG Message Board

  • merckretired2005 merckretired2005 Apr 25, 2012 3:59 PM Flag

    Galena acquisition okay

    in my professional opinion. I've gone over the results of their trials and believe there is about a 80% chance of approval on the data thus far.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • DON'T FORGET ABOUT TBIO as an acquisition!

    • What is your profession? And how do you come to that conclusion?? Thanks in advance...

    • (ASCO) 2012 Annual Meeting. The annual event is being held June 1-5, 2012 in Chicago, Illinois.

      "Safety and Long-Term Maintenance of Anti-HER2 Immunity Following Booster Inoculations of the E75 Breast Cancer Vaccine" (Abstract #2529) will be presented during the poster session, "Developmental Therapeutics -- Clinical Pharmacology and Immunotherapy," on Saturday, June 2, 2012 from 8:00 a.m. to 1:00 p.m. CDT. The discussion session will take place from 12:00 p.m. to 1:00 p.m. CDT.

      Galena will also be hosting a panel entitled, "HER2 Targeted Cancer Therapies" on Monday, June 4, 2012 from 11:30 a.m. to 1:00 p.m. CDT at the Chicago Hilton. The expert panel of breast cancer physicians will include Hope Rugo, M.D., Beth Mittendorf, M.D., and COL George E. Peoples, M.D., F.A.C.S. who will discuss various aspects of the field with a focus on immunotherapy. The panel presentation will include an update of results from the NeuVax(TM) Phase 1/2 clinical trial, and an update on Galena's current Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low-to-Intermediate HER2 Expression with NeuVax Treatment) study.

      About NeuVax(TM) (E75)

      NeuVax consists of the E75 peptide derived from human epidermal growth factor receptor 2 (HER2) combined with the immune adjuvant granulocyte macrophage colony-stimulating factor (GM-CSF). Treatment with NeuVax stimulates cytotoxic (CD8+) T cells in a highly specific manner to target cells expressing any level of HER2. NeuVax is given as an intradermal injection once a month for six months, followed by a booster injection once every six months. Based on a successful Phase 2 trial that achieved its primary endpoint of disease-free survival, the Food and Drug Administration granted NeuVax a Special Protocol Assessment for its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low-to-Intermediate HER2 Expression with NeuVax Treatment) study. The Phase 3 trial is ongoing and additional information on the study can be found at www.neuvax.com

 
RHHBY
37.62-0.28(-0.74%)12:47 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.